key: cord-0807290-uh1j2rn7 authors: Shakhsi-Niaei, Mostafa; Soureshjani, Ehsan Heidari; Babaheydari, Ali Kazemi title: In Silico Comparison of Separate or Combinatorial Effects of Potential Inhibitors of the SARS-CoV-2 Binding Site of ACE2 date: 2021-05-03 journal: Iran J Public Health DOI: 10.18502/ijph.v50i5.6120 sha: 9b953031ab9009a9ade3b1740cc0d833777b1dd7 doc_id: 807290 cord_uid: uh1j2rn7 BACKGROUND: The COVID-19 is a pandemic viral infection with a high morbidity rate, leading to many worldwide deaths since the end of 2019. The RBD (Receptor Binding Domain) of SARS-CoV-2 through its spike utilizes several host molecules to enter host cells. One of the most important ones is the angiotensin-converting enzyme 2 (ACE2), an enzyme normally engaged in renin angiotensin pathway and is responsible for hypertension regulation. As different articles have analyzed separate compounds which can bind ACE2 as the potential virus entry blockers, and each one with a different molecular docking algorithm, in this study we compared all candidate compounds individually as well as their combinations using a unique validated software to introduce most promising ones. METHODS: We collected and prepared a list of all available compounds which potentially can inhibit RBD binding site of the ACE2 from different studies and then reanalyzed and compared them using the Patchdock (ver. 1.3) as a suitable molecular docking algorithm for analysis of separate compounds or their combinations. RESULTS: Saikosaponin A (e.g. in Bupleurum chinense), Baicalin (e.g. in several species in the genus Scutellaria), Glycyrrhizin (Glycyrrhiza glabra), MLN-4760 and Umifenovir better occupied ACE2 to inhibit viral RBD binding and are suggested as the top five inhibitors of the SARS-CoV-2 binding site of ACE2. Their combinatory effects were also inspiring concurrent ACE2 blockade. CONCLUSION: The results propose greatest compounds and their combinatory anti-SARS-CoV-2 effects in order to decrease the time and expenses required for further experimental designs. The coronavirus (2019-nCoV), the causative organism of novel coronavirus pneumonia, is a positive-sense single-strand RNA virus (1) . In this emergency condition, drug repurposing looks better strategy for virus inhibition or decreasing the signs of the disease (2) . Therefore, according to the pathogenesis of this virus, different drugs could be suggested. The SARS-CoV-2 infection and pathogenesis are consisted of different mechanisms at different levels. The first step is the virus' fusion to the host cells. To develop specific SARS-CoV-2 fusion inhibitors, it is essential to study the fusion capacity of SARS-CoV-2 compared to that of previous severe acute respiratory syndrome coronavirus (SARS-CoV). The SARS-CoV-2 similar to SARS-CoV uses the angiotensin-converting enzyme 2 (ACE2) as the receptor for attaching human cells. In fact, the spike of this virus embarks the first contact and binding to the host cell membrane. The spike (S) protein of SARS-CoVs is made up from S1, S2 and transmembrane subunits. However, S1 located in N-terminal of this protein interacts with the host ACE2 to initialize the fusion step (3) . Despite the high similarities of these two SARS viruses, especially in their S2 subunits of spike protein, their S1 subunits which are responsible for ACE2 interaction, contain more differences. These S1 dissimilarities have led to more than 10fold higher affinity of SARS-CoV-2 to ACE2 in comparison with that of SARS-CoV (4). The same domain of the ACE2 is engaged in S1 binding of these two SARS viruses, repurposing of any available drugs or compounds which can inhibit binding of ACE2 to SARS-CoV would be more promising for SARS-CoV-2, particularly when it has many more affinities to ACE2. So far, the ACE2 receptor has been employed to investigate many compounds for the inhibition of SARS-CoV's entrance, using in silico or experimental strategies. For example, 38 Chinese patent drugs were compared via docking screening for the RBD-binding site masking of ACE2 and more potent ones (hesperidin, saikosaponin A, rutin) introduced as potential viral entrance inhibitors (3). Arbidol, a broad spectrum antiviral drug, has been also reported as an entrance inhibitor via ACE2 blockade (5) . Furthermore, ACE2 binding of some natural compounds were checked and reported Scutellarin as the most potent one (6) . Emodin is a known compound for its anti-SARS activity via anti-ACE2/some-protease activitity (7) (8) (9) (10) . On the other hand, other hypertension modulatorsworking through ACE2 catalytic inhibition, such as N-(2-aminoethyl)-1 aziridine-ethanamine (11) and MLN-4760 (12) has been analyzed for their effects on ACE2 conformational changes and further SARS-S inhibitory effects. Therefore, in this study, we reanalyzed previously evaluated compounds by different molecular docking algorithms or experimental studies (from other related studies) for ACE2 blocking, in order to find the inhibitoriest ones for ACE2 blockade against RBD part of the S1 protein in the SARS-CoV-2. Considering different studies, the most effective molecules were selected as the ligands for ACE2. In more detail they were chosen from different studies: Hesperidin, saikosaponin A and rutin (3), Umifenovir (Arbidol) (5), scutellarin, glycyrrhizin, baicalin, hesperetin and nicotianamine (6), emodin (7) (8) (9) (10) , N-(2-aminoethyl)-1 aziridine-ethanamine (11) , and MLN-4760 (12) . Therefore, in our study, we analyzed 13 promising compounds by the molecular docking using Patchdock (ver. 1.3) (13). The structures were downloaded from ChemSpider (http://www.chemspider.com) website and optimized with Chimera 1.13.1 software (14) . The binding structure (S1 protein) of RARS-Cov-2 to ACE2 was modeled according to 6M17 (15) and for SARS-CoV was modeled according to 5WRG (16) obtained from protein data bank (PDB) for further docking analysis. We utilized Patchdock (ver. 1.3) for our molecular docking study (13) . Afterward, the candidate transformations were carried out on complementary patched structures. Then each candidate transformation was compared via the obtained scores by considering the atomic desolvation energy and geometric fit (17) . The PDB coordinate file for each protein and considered ligands made the input parameters for the docking analysis. The clustering RMSD value was set to 4Å. The type of complex was changed to protein-ligand type. We totally analyzed 13 components by docking to ACE2. According to our docking analysis, top five compounds with higher binding affinities (docking score